Cancers,
Год журнала:
2024,
Номер
16(24), С. 4197 - 4197
Опубликована: Дек. 17, 2024
Background:
Cancer
immune
evasion
is
a
multifaceted
process
that
synchronizes
pro-tumoral
infiltration,
immunosuppressive
inflammation,
and
inhibitory
checkpoint
expression
(IC).
Current
immunotherapies
combat
this
issue
by
reinstating
immunosurveillance
of
tumors;
however,
it
benefits
limited
patient
population.
Thus,
more
effective
immunotherapeutic
strategy
warranted
to
cater
specific
populations.
This
investigation
introduces
novel
via
inhibition
master
regulators
(MR-IE).
Methods:
Samples
the
TCGA
Pan-Cancer
Atlas
transcriptomic
data
were
subset
stratified
based
on
IC
estimated
cell
infiltration.
Transcriptomic
analysis
was
conducted
unravel
pathways
associated
with
process.
Transcription
factor
enrichment
survival
analyses
identify
rank
candidate
MR-IEs
per
cancer
type.
Results:
Inhibition
top-ranking
MR-IE
cholangiocarcinoma
(CCA),
MYC,
modulated
gene
protein
PD-L1.
Moreover,
inflammatory
markers,
IFNA21
CX3CL1,
downregulated,
anti-tumoral
cytokines,
IL-18
IL-16,
upregulated.
Lastly,
MYC
potentiated
fourth-generation
anti-folate
receptor
alpha
(FRα)
CAR-T
therapy
against
CCA
cells.
Conclusions:
Cumulatively,
study
highlights
promise
as
potent
for
treatment
offers
list
type
further
validation.
The
combination
of
chemotherapy
and
immunotherapy
for
metastatic
cholangiocarcinoma
(CCA)
offers
promising
improvements
in
survival
response
rates
beyond
traditional
treatments.
TOPAZ-1
KEYNOTE-966
have
demonstrated
the
efficacy
combining
(durvalumab
pembrolizumab)
with
chemotherapy,
even
gallbladder
cancer
(GBC),
a
complete
rate
2.7%
trial.
Advanced
CCA
treated
combinations
has
shown
responses
influenced
by
high
programmed
death-ligand
1
(PD-L1)
or
Epstein-Barr
virus
expression.
These
were
enhanced
radiotherapy
cell
death
protein
(PD-1)
blockade.
A
62-year-old
man
was
diagnosed
unresectable
GBC,
distant
lymphatic
metastases,
local
invasion
liver
segments
4i
5,
colonic
hepatic
flexure,
duodenal
bulb,
pancreatic
head.
Immunohistochemical
examination
revealed
poorly
differentiated
squamous
carcinoma,
without
expression
PD-L1.
Next
generation
sequencing
mutation
ERBB2
R678Q
microsatellite
stable
tumour.
patient
started
chemo-immunotherapy
cisplatin-gemcitabine
plus
durvalumab
June
2022.
After
eight
cycles,
significant
reduction
tumour
volume
markers
reported,
therapy
maintained
through
November
2023.
subsequent
computed
tomography
scans
showed
further
volume,
surgical
resection
performed.
Histological
examinations
confirmed
absence
residual
lymph
node
metastases.
As
2024,
no
signs
disease
recurrence.
Several
reports
conversion
surgery
GBC
exist,
but
data
on
pre-surgical
are
limited.
Furthermore,
pathological
confirmation
raises
several
questions
regarding
need
after
immunotherapy.
Although
effective
control
regression
been
reported
advanced
combined
anti-cytotoxic
T-lymphocyte
associated
4
anti-PD-1
agents
studies
needed
to
identify
reliable
predictive
biomarkers
due
unclear
associations
PD-L1
mutational
burden.
Overall,
treating
CCA,
especially
when
tailored
specific
molecular
profiles.
treatments
may
lead
novel
strategies.
Biomarkers in Medicine,
Год журнала:
2024,
Номер
18(15-16), С. 703 - 715
Опубликована: Авг. 15, 2024
Biliary
tract
cancers
(BTCs)
have
rising
incidence
and
mortality
rates.
Chemotherapy's
limited
efficacy
has
led
to
exploring
new
treatments
like
immunotherapy.
which
offers
modest
benefits.
Moreover,
the
identification
of
reliable
predictive
biomarkers
for
immune
checkpoint
therapy
in
BTCs
remains
elusive,
hindering
personalized
treatment
strategies.
This
review
provides
an
overview
current
landscape
emerging
immunotherapy
response
BTCs.
We
discuss
incremental
benefits
combination
evolving
role
managing
advanced
BTC.
Additionally,
we
highlight
need
robust
optimize
outcomes
foster
a
more
individualized
approach
patient
care.
aim
identify
promising
research
avenues
strategies
enhance
therapeutic
survival
Cancers,
Год журнала:
2024,
Номер
16(24), С. 4197 - 4197
Опубликована: Дек. 17, 2024
Background:
Cancer
immune
evasion
is
a
multifaceted
process
that
synchronizes
pro-tumoral
infiltration,
immunosuppressive
inflammation,
and
inhibitory
checkpoint
expression
(IC).
Current
immunotherapies
combat
this
issue
by
reinstating
immunosurveillance
of
tumors;
however,
it
benefits
limited
patient
population.
Thus,
more
effective
immunotherapeutic
strategy
warranted
to
cater
specific
populations.
This
investigation
introduces
novel
via
inhibition
master
regulators
(MR-IE).
Methods:
Samples
the
TCGA
Pan-Cancer
Atlas
transcriptomic
data
were
subset
stratified
based
on
IC
estimated
cell
infiltration.
Transcriptomic
analysis
was
conducted
unravel
pathways
associated
with
process.
Transcription
factor
enrichment
survival
analyses
identify
rank
candidate
MR-IEs
per
cancer
type.
Results:
Inhibition
top-ranking
MR-IE
cholangiocarcinoma
(CCA),
MYC,
modulated
gene
protein
PD-L1.
Moreover,
inflammatory
markers,
IFNA21
CX3CL1,
downregulated,
anti-tumoral
cytokines,
IL-18
IL-16,
upregulated.
Lastly,
MYC
potentiated
fourth-generation
anti-folate
receptor
alpha
(FRα)
CAR-T
therapy
against
CCA
cells.
Conclusions:
Cumulatively,
study
highlights
promise
as
potent
for
treatment
offers
list
type
further
validation.
